{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:17:08Z","timestamp":1760267828685,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with multiple myeloma (MM), an age-dependent neoplasm of antibody-producing plasma cells, have compromised immune systems and might be at increased risk for severe COVID-19 outcomes. This study characterizes risk factors associated with clinical indicators of COVID-19 severity and all-cause mortality in myeloma patients utilizing NCATS\u2019 National COVID Cohort Collaborative (N3C) database. The N3C consortium is a large, centralized data resource representing the largest multi-center cohort of COVID-19 cases and controls nationwide (&gt;16 million total patients, and &gt;6 million confirmed COVID-19+ cases to date). Our cohort included myeloma patients (both inpatients and outpatients) within the N3C consortium who have been diagnosed with COVID-19 based on positive PCR or antigen tests or ICD-10-CM diagnosis code. The outcomes of interest include all-cause mortality (including discharge to hospice) during the index encounter and clinical indicators of severity (i.e., hospitalization\/emergency department\/ED visit, use of mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)). Finally, causal inference analysis was performed using the Coarsened Exact Matching (CEM) and Propensity Score Matching (PSM) methods. As of 05\/16\/2022, the N3C consortium included 1,061,748 cancer patients, out of which 26,064 were MM patients (8,588 were COVID-19 positive). The mean age at COVID-19 diagnosis was 65.89\u2009years, 46.8% were females, and 20.2% were of black race. 4.47% of patients died within 30\u2009days of COVID-19 hospitalization. Overall, the survival probability was 90.7% across the course of the study. Multivariate logistic regression analysis showed histories of pulmonary and renal disease, dexamethasone, proteasome inhibitor\/PI, immunomodulatory\/IMiD therapies, and severe Charlson Comorbidity Index\/CCI were significantly associated with higher risks of severe COVID-19 outcomes. Protective associations were observed with blood-or-marrow transplant\/BMT and COVID-19 vaccination. Further, multivariate Cox proportional hazard analysis showed that high and moderate CCI levels, International Staging System (ISS) moderate or severe stage, and PI therapy were associated with worse survival, while BMT and COVID-19 vaccination were associated with lower risk of death. Finally, matched sample average treatment effect on the treated (SATT) confirmed the causal effect of BMT and vaccination status as top protective factors associated with COVID-19 risk among US patients suffering from multiple myeloma. To the best of our knowledge, this is the largest nationwide study on myeloma patients with COVID-19.<\/jats:p>","DOI":"10.1038\/s41408-023-00901-y","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:02:22Z","timestamp":1701918142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-7070","authenticated-orcid":false,"given":"Amit Kumar","family":"Mitra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1560-7772","authenticated-orcid":false,"given":"Ujjal Kumar","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-1703","authenticated-orcid":false,"given":"Vithal","family":"Madhira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-7765","authenticated-orcid":false,"given":"Yu Raymond","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4917-6173","authenticated-orcid":false,"given":"Jing","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"Sharafeldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umit","family":"Topaloglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"National COVID Cohort Collaborative Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Chute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Moffitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Haendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"901_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jmv.25678","volume":"92","author":"H Lu","year":"2020","unstructured":"Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92:401\u20132.","journal-title":"J Med Virol"},{"key":"901_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/d41586-021-03614-z","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway E, Ledford H. How bad is Omicron? What scientists know so far. Nature. 2021;600:197\u20139.","journal-title":"Nature"},{"key":"901_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.7150\/thno.51471","volume":"11","author":"AS Pathania","year":"2021","unstructured":"Pathania AS, Prathipati P, Abdul BA, Chava S, Katta SS, Gupta SC, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges. Theranostics. 2021;11:731\u201353.","journal-title":"Theranostics"},{"key":"901_CR4","doi-asserted-by":"crossref","unstructured":"Sharafeldin N, Bates B, Song Q, Madhira V, Yan Y, Dong S, et al. Outcomes of COVID-19 in patients with cancer: report from the National COVID Cohort Collaborative (N3C). J Clin Oncol. 2021;39:2232\u201346.","DOI":"10.1200\/JCO.21.01074"},{"key":"901_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ajh.23390","volume":"88","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:226\u201335.","journal-title":"Am J Hematol"},{"key":"901_CR6","doi-asserted-by":"crossref","unstructured":"Wade JC. Viral infections in patients with hematological malignancies. Hematol Am Soc Hematol Educ Program 2006:368\u201374.","DOI":"10.1182\/asheducation-2006.1.368"},{"key":"901_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.idc.2019.01.001","volume":"33","author":"S Atkins","year":"2019","unstructured":"Atkins S, He F. Chemotherapy and beyond: infections in the era of old and new treatments for hematologic malignancies. Infect Dis Clin North Am. 2019;33:289\u2013309.","journal-title":"Infect Dis Clin North Am"},{"key":"901_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2643-3230.BCD-20-0177","volume":"2","author":"MV Dhodapkar","year":"2021","unstructured":"Dhodapkar MV, Dhodapkar KM, Ahmed R. Viral immunity and vaccines in hematologic malignancies: implications for COVID-19. Blood Cancer Discov. 2021;2:9\u201312.","journal-title":"Blood Cancer Discov"},{"key":"901_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00372-5","volume":"10","author":"J Mart\u00ednez-L\u00f3pez","year":"2020","unstructured":"Mart\u00ednez-L\u00f3pez J, Mateos M-V, Encinas C, Sureda A, Hern\u00e1ndez-Rivas J\u00c1, Lopez de la Gu\u00eda A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103.","journal-title":"Blood Cancer J"},{"key":"901_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00588-z","volume":"11","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Mu\u00f1oz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11:198.","journal-title":"Blood Cancer J"},{"key":"901_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","volume":"28","author":"MA Haendel","year":"2021","unstructured":"Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, et al. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inf Assoc. 2021;28:427\u201343.","journal-title":"J Am Med Inf Assoc"},{"key":"901_CR12","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1200\/JCO.21.02419","volume":"40","author":"Q Song","year":"2022","unstructured":"Song Q, Bates B, Shao YR, Hsu F-C, Liu F, Madhira V, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative. J Clin Oncol. 2022;40:1414\u201327.","journal-title":"J Clin Oncol"},{"key":"901_CR13","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"901_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v030.i09","volume":"30","author":"S Iacus","year":"2009","unstructured":"Iacus S, King G, Porro G. cem: Software for coarsened exact matching. J Stat Softw. 2009;30:1\u201327.","journal-title":"J Stat Softw"},{"key":"901_CR15","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1073\/pnas.1510489113","volume":"113","author":"S Athey","year":"2016","unstructured":"Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci USA. 2016;113:7353\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"901_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09097-5","volume":"21","author":"RS Greenberg","year":"2021","unstructured":"Greenberg RS, Ruddy JA, Boyarsky BJ, Werbel WA, Garonzik-Wang JM, Segev DL, et al. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma. BMC Cancer. 2021;21:1354.","journal-title":"BMC Cancer"},{"key":"901_CR17","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1200\/JCO.21.02257","volume":"40","author":"AK Nooka","year":"2022","unstructured":"Nooka AK, Shanmugasundaram U, Cheedarla N, Verkerke H, Edara VV, Valanparambil R, et al. Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma. J Clin Oncol. 2022;40:3057\u201364.","journal-title":"J Clin Oncol"},{"key":"901_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaoncol.2021.5942","volume":"8","author":"E Terpos","year":"2022","unstructured":"Terpos E, Rajkumar SV, Leung N. Neutralizing antibody testing in patients with multiple myeloma following COVID-19 vaccination. JAMA Oncol. 2022;8:201.","journal-title":"JAMA Oncol"},{"key":"901_CR19","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","volume":"8","author":"A Sharma","year":"2021","unstructured":"Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185\u201393.","journal-title":"Lancet Haematol"},{"key":"901_CR20","doi-asserted-by":"publisher","unstructured":"Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, et al. Reduced absolute count of monocytes in patients carrying hematological neoplasms and SARS-CoV2 infection. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14051173.","DOI":"10.3390\/cancers14051173"},{"key":"901_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ajh.24236","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91:90\u2013100.","journal-title":"Am J Hematol"},{"key":"901_CR22","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011;29:1916\u201323.","DOI":"10.1200\/JCO.2010.34.0760"},{"key":"901_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone in relapsed\/relapsed and refractory myeloma: outcomes by prior treatment. Blood. 2016;127:713\u201321.","journal-title":"Blood"},{"key":"901_CR24","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents proteasome inhibitors: a novel class of potent and effective antitumor agents. Direct. 1999;59:2615\u201322.","journal-title":"Direct"},{"key":"901_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46:673\u201383.","journal-title":"Clin Chem"},{"key":"901_CR26","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013;19:3337\u201344.","DOI":"10.1158\/1078-0432.CCR-12-1881"},{"key":"901_CR27","doi-asserted-by":"crossref","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10\u2009years later. Blood. 2012;120:947\u201359.","DOI":"10.1182\/blood-2012-04-403733"},{"key":"901_CR28","doi-asserted-by":"crossref","unstructured":"Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121:893\u20137.","DOI":"10.1182\/blood-2012-10-459883"},{"key":"901_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/ejh.13502","volume":"105","author":"KH Susek","year":"2020","unstructured":"Susek KH, Gran C, Ljunggren H-G, Alici E, Nahi H. Outcome of COVID-19 in multiple myeloma patients in relation to treatment. Eur J Haematol. 2020;105:751\u20134.","journal-title":"Eur J Haematol"},{"key":"901_CR30","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1111\/bjh.16874","volume":"190","author":"G Cook","year":"2020","unstructured":"Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190:e83\u20136.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00901-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:03:39Z","timestamp":1701918219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00901-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00901-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"type":"electronic","value":"2044-5385"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"24 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}